SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
1.400
-0.020 (-1.41%)
Oct 29, 2024, 4:00 PM EDT - Market closed
SCYNEXIS Revenue
SCYNEXIS had revenue of $736.00K in the quarter ending June 30, 2024, a decrease of -99.44%. This brings the company's revenue in the last twelve months to $9.67M, down -92.88% year-over-year. In the year 2023, SCYNEXIS had annual revenue of $140.14M with 2,652.72% growth.
Revenue (ttm)
$9.67M
Revenue Growth
-92.88%
P/S Ratio
7.07
Revenue / Employee
$333,310
Employees
29
Market Cap
53.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 140.14M | 135.05M | 2,652.72% |
Dec 31, 2022 | 5.09M | -8.07M | -61.32% |
Dec 31, 2021 | 13.16M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | 121.00K | -136.00K | -52.92% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fortress Biotech | 82.62M |
LakeShore Biopharma | 79.42M |
Champions Oncology | 51.66M |
Qilian International Holding Group | 29.87M |
Kronos Bio | 8.41M |
Aligos Therapeutics | 7.97M |
Affimed | 7.96M |
Lucid Diagnostics | 3.80M |
SCYX News
- 19 days ago - SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 26 days ago - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - GlobeNewsWire
- 2 months ago - SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports - GlobeNewsWire
- 6 months ago - SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) - GlobeNewsWire
- 7 months ago - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - GlobeNewsWire